Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents (AS)
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
California
-
Huntington Beach, California, Förenta staterna, 92647
- Rekrytering
- Retina Consultants of Southern California
-
Kontakt:
- Hani Salehi-Had, MD
- Telefonnummer: 657-227-9496
- E-post: i.gomez@retinasocal.com
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30909
- Rekrytering
- Southeast Retina Center, P.C.
-
Kontakt:
- Dennis M Marcus, MD
- Telefonnummer: 709-650-0061
- E-post: amitchell@southeastretina.com
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02118
- Rekrytering
- Boston Medical Center Corporation
-
Kontakt:
- Steven D Ness, MD
- Telefonnummer: 617-414-4020
- E-post: sreevardhan.alluri@bmc.org
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Rekrytering
- Henry Ford Health System
-
Kontakt:
- Paul A Edwards, MD
- Telefonnummer: 313-874-9167
- E-post: mdakhil1@hfhs.org
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic
-
Kontakt:
- Andrew J. Barkmeier, MD
- Telefonnummer: 507-538-8119
- E-post: Taylor.Laura2@mayo.edu
-
-
Pennsylvania
-
Monroeville, Pennsylvania, Förenta staterna, 15146
- Rekrytering
- Retina-Vitreous Consultants, Inc.
-
Kontakt:
- Shripaad Y Shukla, MD
- Telefonnummer: 412-683-5300
- E-post: merlottil@retinapittsburgh.com
-
Sewickley, Pennsylvania, Förenta staterna, 15143
- Rekrytering
- Pittsburgh Clinical Trial Consortium
-
Kontakt:
- Leanne T. Labriola, DO, MBA
- Telefonnummer: 412-301-5326
- E-post: franco@pghtrials.com
-
-
Texas
-
Beaumont, Texas, Förenta staterna, 77707
- Rekrytering
- Retina Consultants of Texas
-
Kontakt:
- William Pearce, MD
- Telefonnummer: 9008335921
- E-post: alaida.jimenez@retinaconsultantstexas.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key inclusion criteria:
- Age ≥18 years
- Diagnosed with Type 1 or Type 2 diabetes
- Best corrected visual acuity 20/320 or better (Snellen) (≥24 ETDRS letters)
- At least 1 eye with CI-DME requiring treatment
- Able and willing to provide informed consent.
Key exclusion criteria:
- Ocular or systemic condition, aside from diabetes mellitus (DM), that is likely to affect the assessment of DRSS, DME, or the functioning of the neural retina.
- Previous treatment of any kind for diabetic retinopathy or DME
- Any condition that may preclude adequate imaging of the macula (e.g. dense cataract or other media opacity, ptosis)
- History of rhegmatogenous retinal detachment or macular hole
- History of vitrectomy
- Intraocular surgery (including cataract surgery) within 4 months prior to enrollment or anticipated within the next 6 months
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Mild center-involved diabetic macular edema
Eyes with optical coherence tomography central subfield thickness <75 µm above DRCR standard thresholds of Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men |
All study eyes will receive an injection of anti-VEGF at baseline, 4, and 8 weeks. The participant will then be assessed for treatment every 8 weeks. At and after the 16-week visit, an injection will only be given if the eye has center-involved DME or visual acuity worse than 20/20 (presumed to be due to DME). Otherwise, an injection will not be given. The follow-up interval remains 8 weeks regardless of whether an injection is given or deferred. However, if an injection is deferred and the participant experiences vision issues or other symptoms, they may return for evaluation prior to 8 weeks (e.g., in 4 weeks) and can receive an injection (provided it has been at least 21 days since the last injection).
Andra namn:
|
|
Aktiv komparator: Moderate Center-involved diabetic macular edema
Eyes with OCT central subfield thickness 75 to <175 µm above DRCR standard thresholds of: Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men |
All study eyes will receive an injection of anti-VEGF at baseline, 4, and 8 weeks. The participant will then be assessed for treatment every 8 weeks. At and after the 16-week visit, an injection will only be given if the eye has center-involved DME or visual acuity worse than 20/20 (presumed to be due to DME). Otherwise, an injection will not be given. The follow-up interval remains 8 weeks regardless of whether an injection is given or deferred. However, if an injection is deferred and the participant experiences vision issues or other symptoms, they may return for evaluation prior to 8 weeks (e.g., in 4 weeks) and can receive an injection (provided it has been at least 21 days since the last injection).
Andra namn:
|
|
Aktiv komparator: Severe Center-involved diabetic macular edema
Severe CI-DME: Eyes with OCT central subfield thickness >=175µm above DRCR standard thresholds of Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men |
All study eyes will receive an injection of anti-VEGF at baseline, 4, and 8 weeks. The participant will then be assessed for treatment every 8 weeks. At and after the 16-week visit, an injection will only be given if the eye has center-involved DME or visual acuity worse than 20/20 (presumed to be due to DME). Otherwise, an injection will not be given. The follow-up interval remains 8 weeks regardless of whether an injection is given or deferred. However, if an injection is deferred and the participant experiences vision issues or other symptoms, they may return for evaluation prior to 8 weeks (e.g., in 4 weeks) and can receive an injection (provided it has been at least 21 days since the last injection).
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in multifocal pupillographic objective perimetry (mfPOP) response delays
Tidsram: Baseline to 1 year
|
mfPOP response delays measured using the Objective Field Analyzer (OFA) |
Baseline to 1 year
|
|
Change in area under the log contrast sensitivity function (AULCSF)
Tidsram: Baseline to 1 year
|
AULCSF as measured by the Adaptive Sensory Testing (AST) Manifold contrast sensitivity testing system |
Baseline to 1 year
|
|
Change in electroretinography parameter
Tidsram: Baseline to 1 year
|
Measured by the RETeval device |
Baseline to 1 year
|
|
Change in reading performance
Tidsram: Baseline to 1 year
|
Measured by the MNREAD test |
Baseline to 1 year
|
|
Change in visual field function
Tidsram: Baseline to 1 year
|
Measured by Humphrey Visual Field testing |
Baseline to 1 year
|
|
Change in diabetic retinopathy severity
Tidsram: Baseline to 1 year
|
Assessed by ultra-widefield (UWF) color fundus photography |
Baseline to 1 year
|
|
Change in retinal vascular pathology
Tidsram: Baseline to 1 year
|
Assessed by ultra-widefield fluorescein angiography (UWF-FA) |
Baseline to 1 year
|
|
Change in retinal structure
Tidsram: Baseline to 1 year
|
measured by optical coherence tomography (OCT) |
Baseline to 1 year
|
|
Change in retinal microvascular parameter
Tidsram: Baseline to 1 year
|
Measured by optical coherence tomography angiography (OCTA) |
Baseline to 1 year
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- Protocol AS (1)
- UG1EY014231 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .